(2S,4R)-1-[(2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]-4-[5-(4-methoxyphenyl)tetrazol-2-yl]pyrrolidine-2-carboxylic acid | 1160633-79-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-1-[(2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]-4-[5-(4-methoxyphenyl)tetrazol-2-yl]pyrrolidine-2-carboxylic acid
• CAS: 1160633-79-3
• 化学式: C₂₄H₃₄N₆O₆
• 分子量: 502.571
• InChiKey: FLXSMZBEBNSLRM-BPQIPLTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  149
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (1R,2R)-1-amino-N-(cyclopropaneylsulfonyl)-2-(difluoromethyl)cyclopropanecarboxamide hydrochloride 、 (2S,4R)-1-[(2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]-4-[5-(4-methoxyphenyl)tetrazol-2-yl]pyrrolidine-2-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 tert-butyl N-[(2S)-1-[(2S,4R)-2-[[(1R,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-(difluoromethyl)cyclopropyl]carbamoyl]-4-[5-(4-methoxyphenyl)tetrazol-2-yl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
  参考文献：
  名称：

  [EN] FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
  [FR] COMPOSÉS À BASE DE TRIPEPTIDES FLUORÉS INHIBANT LA SÉRINE PROTÉASE DU VHC

  摘要：

  公开号：

  WO2009076173A3
• 作为产物：
  描述：

  methyl (2S,4R)-1-[(2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]-4-[5-(4-methoxyphenyl)tetrazol-2-yl]pyrrolidine-2-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 18.0h， 以100%的产率得到(2S,4R)-1-[(2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]-4-[5-(4-methoxyphenyl)tetrazol-2-yl]pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  [EN] FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
  [FR] COMPOSÉS À BASE DE TRIPEPTIDES FLUORÉS INHIBANT LA SÉRINE PROTÉASE DU VHC

  摘要：

  公开号：

  WO2009076173A3

文献信息

• HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090202485A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090197888A1

  公开（公告）日：2009-08-06

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8101567B2
  申请人：——

  公开号：US8101567B2

  公开（公告）日：2012-01-24
• US8940688B2
  申请人：——

  公开号：US8940688B2

  公开（公告）日：2015-01-27
• [EN] HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA SÉRINE PROTÉASE DU VHC TRIPEPTIDIQUE CONTENANT UN HÉTÉROARYLE
  申请人：ENANTA PHARM INC

  公开号：WO2009094438A1

  公开（公告）日：2009-07-30

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.